These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2827906)

  • 21. Release of platelet activating factor by the isolated kidney is not linked to the production of prostaglandins.
    Nies AS; Tunney A; Barden A; Sturm M; Vandongen R
    J Pharmacol Exp Ther; 1991 Nov; 259(2):590-4. PubMed ID: 1941608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of vascular actions of PAF.
    Piper PJ; Stanton AW; Stewart AG
    Int J Tissue React; 1987; 9(1):15-7. PubMed ID: 3036733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative inotropic effect of platelet-activating factor: association with a decrease in intracellular sodium activity.
    Robertson DA; Wang DY; Lee CO; Levi R
    J Pharmacol Exp Ther; 1988 Apr; 245(1):124-8. PubMed ID: 3361438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of cardiac and hemodynamic effects of platelet-activating factor-acether and leukotriene D4 in anesthetized dogs.
    Fiedler VB; Mardin M; Abram TS
    Basic Res Cardiol; 1987; 82(2):197-208. PubMed ID: 3606544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of platelet-activating factor, thromboxane A2 and leukotriene D4 on isolated perfused rat liver.
    Cui S; Shibamoto T; Liu W; Takano H; Kurata Y
    Prostaglandins Other Lipid Mediat; 2006 Jul; 80(1-2):35-45. PubMed ID: 16846785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet-activating factor and bacteremia-induced pulmonary hypertension.
    Clavijo LC; Carter MB; Matheson PJ; Wills-Frank LA; Wilson MA; Wead WB; Garrison RN
    J Surg Res; 2000 Feb; 88(2):173-80. PubMed ID: 10644485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart.
    Loucks EB; Godin DV; Walley KR; McManus BM; Rahimian R; Granville DJ; Hong JM; Aktary FM; Qayumi AK
    Can J Cardiol; 2003 Mar; 19(3):267-74. PubMed ID: 12677282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of peptide leukotrienes on cardiac dynamics in rat, cat, and guinea pig hearts.
    Roth DM; Lefer DJ; Hock CE; Lefer AM
    Am J Physiol; 1985 Sep; 249(3 Pt 2):H477-84. PubMed ID: 4037097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of PGD2 on cardiac contractility: a negative inotropism secondary to coronary vasoconstriction conceals a primary positive inotropic action.
    Hattori Y; Levi R
    J Pharmacol Exp Ther; 1986 Jun; 237(3):719-24. PubMed ID: 3012066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of PAF on cardiac function and eicosanoid release in the isolated perfused rat heart: comparison between normotensive and spontaneously hypertensive rats.
    Giessler C; Pönicke K; Steinborn C; Brodde OE
    Basic Res Cardiol; 1995; 90(4):337-47. PubMed ID: 8534259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Similar coronary vascular effects in the rat perfused heart of platelet-activating factor structural analogues with agonist and antagonist properties.
    Man RY; Kinnaird AA
    Br J Pharmacol; 1995 Nov; 116(5):2359-64. PubMed ID: 8581269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism.
    Baker KE; Curtis MJ
    Br J Pharmacol; 2004 May; 142(2):352-66. PubMed ID: 15066909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive inotropic effects of low concentrations of leukotrienes C4 and D4 in rat heart.
    Karmazyn M; Moffat MP
    Am J Physiol; 1990 Oct; 259(4 Pt 2):H1239-46. PubMed ID: 1699437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukotrienes: possible mediators in bronchial asthma.
    Piper PJ
    Eur J Respir Dis Suppl; 1983; 129():45-64. PubMed ID: 6317422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the coronary vascular responses to platelet-activating factor in the isolated perfused heart.
    Hu WM; Choy PC; Man RY
    Lipids; 1991 Sep; 26(9):700-4. PubMed ID: 1762514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The synthesis, release and action of leukotrienes in the isolated, unstimulated, buffer-perfused rat heart.
    Garlick PB; Mashiter GD; Di Marzo V; Tippins JR; Morris HR; Maisey MN
    J Mol Cell Cardiol; 1989 Nov; 21(11):1101-10. PubMed ID: 2607544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4 in the rat lung.
    Davidson D; Drafta D
    J Appl Physiol (1985); 1992 Sep; 73(3):955-61. PubMed ID: 1400062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet-activating factor-induced coronary constriction in the isolated perfused guinea pig heart and antagonistic effects of the PAF antagonist WEB 2086.
    Felix SB; Steger A; Baumann G; Busch R; Ochsenfeld G; Berdel WE
    J Lipid Mediat; 1990; 2(1):9-20. PubMed ID: 2133268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of exogenous 5,8,11,14,17-eicosapentaenoic acid on cardiac anaphylaxis.
    Juan H; Peskar BA; Simmet T
    Br J Pharmacol; 1987 Feb; 90(2):315-25. PubMed ID: 2881590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective action of prostaglandin E1 (PGE1) against constrictor mediators in isolated rat heart and lung.
    Terashita Z; Stahl GL; Lefer AM
    Biochem Pharmacol; 1988 Jul; 37(13):2659-65. PubMed ID: 2839198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.